Tetraphase Pharmaceuticals Inc (TTPH.OQ)
3.02USD
18 Apr 2018
-- (--)
$3.02
--
--
--
--
308,976
$8.75
$2.06
Latest Key Developments (Source: Significant Developments)
Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections
Jan 2 (Reuters) - Tetraphase Pharmaceuticals Inc
Millennium Management Llc Reports 5.3 Pct Passive Stake In Tetraphase Pharmaceuticals As On Dec 14
Dec 20 (Reuters) - Millennium Management Llc::MILLENNIUM MANAGEMENT LLC REPORTS 5.3 PERCENT PASSIVE STAKE IN TETRAPHASE PHARMACEUTICALS AS ON DEC 14 - SEC FILING. Full Article
Tetraphase Pharmaceuticals Q3 loss per share $0.63
Nov 2 (Reuters) - Tetraphase Pharmaceuticals Inc
Tetraphase Pharmaceuticals signs commercial supply agreement with Finorga
Oct 20 (Reuters) - Tetraphase Pharmaceuticals Inc
TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CFO
Oct 16 (Reuters) - Tetraphase Pharmaceuticals Inc
Tetraphase pharmaceuticals doses first patient in IGNITE4 phase 3 clinical trial of Eravacycline in cIAI
Tetraphase Pharmaceuticals Inc
Tetraphase Pharmaceuticals reports Q2 loss per share $0.47
Tetraphase Pharmaceuticals Inc
BRIEF-Tetraphase Pharma Q4 Loss Per Share $0.46
* TETRAPHASE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS, HIGHLIGHTS ACHIEVEMENTS AND KEY 2018 MILESTONES